GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31

GYRE THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$6.09+0.01 (+0.16%)

Close on Oct 19, 2026

Community

Notes and questions about Gyre Therapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Gyre Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Oct 31, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is GYRE.

Revenue growth13.5% · median 32.4%

Gross margin94.3% · median 76.7%

Operating margin-14.0% · median -311.7%

Net margin-23.6% · median -235.0%

Advertisement
300 × 250